5005 ORAL Exploratory Subgroup Analysis of the TAMRAD Phase 2 GINECO Trial Comparing Tamoxifen (TAM) Plus Everolimus (RAD) With TAM Alone in Patients With Hormone-receptor-positive, HER2-negative Metastatic Breast Cancer (mBC) With Prior Exposure to Aromatase Inhibitors (Als): Implication for Research Strategies
European Journal of Cancer(2011)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要